These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31203378)

  • 1. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
    Aung MM; Slade K; Freeman LAR; Kos K; Whatmore JL; Shore AC; Gooding KM
    Diabetologia; 2019 Sep; 62(9):1701-1711. PubMed ID: 31203378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
    Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
    Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
    Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.
    Smits MM; Muskiet MH; Tonneijck L; Kramer MH; Diamant M; van Raalte DH; Serné EH
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1538-43. PubMed ID: 25908765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).
    Htike ZZ; Yates T; Brady EM; Webb D; Gray LJ; Swarbrick D; McCann GP; Khunti K; Davies MJ
    Cardiovasc Diabetol; 2016 Jul; 15(1):102. PubMed ID: 27440110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of exenatide and liraglutide in Denmark: a drug utilization study.
    Pottegård A; Bjerregaard BK; Larsen MD; Larsen KS; Hallas J; Knop FK; Moreno SI
    Eur J Clin Pharmacol; 2014 Feb; 70(2):205-14. PubMed ID: 24145815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
    De Ciuceis C; Agabiti-Rosei C; Rossini C; Caletti S; Coschignano MA; Ferrari-Toninelli G; Ragni G; Cappelli C; Cerudelli B; Airò P; Scarsi M; Tincani A; Porteri E; Rizzoni D
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):369-378. PubMed ID: 30203268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.
    Fontana J; Kučera O; Mezera V; Anděl M; Červinková Z
    Physiol Res; 2017 Nov; 66(5):833-844. PubMed ID: 28730824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.